Recommendations for Management of Secondary Antibody Deficiency in Multiple Myeloma

Giralt, Sergio, Jolles, Stephen, Kerre, Tessa, Lazarus, Hillard M., Mustafa, S. Shahzad, Papanicolaou, Genovefa A., Ria, Roberto, Vinh, Donald C. and Wingard, John R. 2023. Recommendations for Management of Secondary Antibody Deficiency in Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia 23 , pp. 719-732. 10.1016/j.clml.2023.05.008

Preview

PDF - Published Version Available under License Creative Commons Attribution. Download (1MB) | Preview

Abstract

Secondary antibody deficiency (SAD) is a subtype of secondary immunodeficiency characterized by low serum antibody concentrations (hypogammaglobulinemia) or poor antibody function. SAD is common in patients with multiple myeloma (MM) due to underlying disease pathophysiology and treatment-related immune system effects. Patients with SAD are more susceptible to infections and infection-related morbidity and mortality. With therapeutic advancements improving MM disease control and survival, it is increasingly important to recognize and treat the often-overlooked concurrent immunodeficiency present in patients with MM. The aims of this review are to define SAD and its consequences in MM, increase SAD awareness, and provide recommendations for SAD management. Based on expert panel discussions at a standalone meeting and supportive literature, several recommendations were made. Firstly, all patients with MM should be suspected to have SAD regardless of serum antibody concentrations. Patients should be evaluated for immunodeficiency at MM diagnosis and stratified into management categories based on their individualized risk of SAD and infection. Infection-prevention strategy education, early infection reporting, and anti-infective prophylaxis are key. We recommend prophylactic antibiotics or immunoglobulin replacement therapy (IgRT) should be considered in patients with severe hypogammaglobulinemia associated with a recurrent or persistent infection. To ensure an individualized and efficient treatment approach is utilized, patient's immunoglobin G concentration and infection burden should be closely monitored throughout treatment. Patient choice regarding route and IgRT treatment is also key in reducing treatment burden. Together, these recommendations and proposed management algorithms can be used to aid physician decision-making to improve patient outcomes.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Publisher:	Elsevier
ISSN:	2152-2650
Funders:	CSLB
Date of First Compliant Deposit:	21 August 2023
Last Modified:	04 Oct 2023 07:28
URI:	https://orca.cardiff.ac.uk/id/eprint/160578

Actions (repository staff only)

Edit Item